SEC Comment Letter for RedHill Biopharma Ltd. (RDHL) (CIK 0001553846) (RDHL) — Jul 31, 2019
RedHill Biopharma Ltd. (RDHL) (CIK 0001553846)
Date: July 31, 2019 · CIK: 0001553846 · Accession: 0000000000-19-011822
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232777
Letter
July 30, 2019 Dror Ben-Asher Chief Executive Officer RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv 6473921 Israel Re:RedHill Biopharma Ltd. Registration Statement on Form F-3 Filed July 24, 2019 File No. 333-232777 Dear Mr. Ben-Asher: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Donald Field at 202-551-3680 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
July 30, 2019
Dror Ben-Asher
Chief Executive Officer
RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv 6473921
Israel
Re:RedHill Biopharma Ltd.
Registration Statement on Form F-3
Filed July 24, 2019
File No. 333-232777
Dear Mr. Ben-Asher:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Donald Field at 202-551-3680 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance